Health Outcomes Research, The Brod Group, California, USA.
Market Access, Ascendis Pharma, Inc., Palo Alto, California, USA.
Am J Med Genet A. 2021 Jan;185(1):33-45. doi: 10.1002/ajmg.a.61903. Epub 2020 Oct 20.
This study's purpose was to provide qualitative evidence to support the development of two observer-reported outcome measures assessing the physical symptoms/complications of achondroplasia in children and impacts on children's quality of life. Individual/focus group concept elicitation interviews were conducted with parents of children aged 2 to <12 years with achondroplasia and experts. Qualitative analysis of transcripts, based on an adapted grounded theory approach, informed item generation and measure development. Cognitive debriefing (CD) interviews were conducted with parents to confirm relevance and understanding. Thirty-six parents participated in concept elicitation interviews. The analysis identified major physical symptoms/complications and impacts of achondroplasia, which informed the development of the Achondroplasia Child Experience Measures (ACEMs): ACEM-Symptom and ACEM-Impact. ACEM-Symptom was comprised of eight major symptoms/complications including pain (58%), ear infections/fluid in ear (56%), and low stamina/tiring easily (56%). ACEM-Impact consisted of 31 major impacts in the domains of daily functioning, emotional well-being, social well-being, and need for assistance/adaptive devices. Impacts on functioning included difficulty reaching objects/high places (89%) and toileting (67%). Emotional impacts included feeling different (53%) and feeling frustrated/annoyed (47%). Social impacts included difficulty participating in sports/physical play (86%) and being treated as younger than age (83%). Following CD interviews with 16 additional parents, validation-ready ACEM measures were generated. The study improves our understanding of the experiences of children with achondroplasia and provides evidence supporting the content validity of the ACEMs. Validated ACEMs may be used to assess potential benefits of future treatments for comorbidities of achondroplasia.
本研究旨在提供定性证据,支持开发两种观察者报告的结局测量工具,以评估成骨不全症儿童的身体症状/并发症及其对儿童生活质量的影响。对 2 至<12 岁成骨不全症儿童的父母和专家进行了个体/焦点小组概念发掘访谈。基于改编的扎根理论方法对转录本进行定性分析,为项目生成和测量开发提供信息。对父母进行认知审核(CD)访谈以确认相关性和理解。36 位父母参加了概念发掘访谈。分析确定了成骨不全症的主要身体症状/并发症和影响,为成骨不全症儿童体验测量工具(ACEMs)的开发提供了信息:ACEM-症状和 ACEM-影响。ACEM-症状包括疼痛(58%)、耳部感染/耳内积液(56%)和低耐力/容易疲劳(56%)等 8 种主要症状/并发症。ACEM-影响包括日常功能、情绪健康、社会健康和需要帮助/适应性设备等领域的 31 个主要影响。功能障碍影响包括难以够到物体/高处(89%)和上厕所(67%)。情绪影响包括感觉与众不同(53%)和感到沮丧/恼怒(47%)。社会影响包括难以参加运动/身体活动(86%)和被视为比实际年龄小(83%)。对另外 16 位父母进行认知审核访谈后,生成了准备就绪进行验证的 ACEM 测量工具。该研究增进了我们对成骨不全症儿童体验的理解,并提供了支持 ACEM 内容有效性的证据。验证后的 ACEM 可用于评估未来治疗成骨不全症合并症的潜在益处。